DUBLIN - Mallinckrodt (OTC:MNKKQ) plc, a global specialty pharmaceutical firm, has expanded its Board of Directors with the addition of four seasoned professionals, effective immediately. The company confirmed Paul Bisaro's return as Board Chair, a role he previously held from June 2022 to November 2023. Alongside Bisaro, Katina Dorton, Abbas Hussain, and Wesley Wheeler have been appointed to the board, bringing a wealth of experience in pharmaceuticals, healthcare, finance, and operations.
Siggi Olafsson remains at the helm as President, CEO, and board member, having signed a new employment agreement. Olafsson expressed confidence in the newly fortified board, saying, "The actions we took in 2023 have made Mallinckrodt a stronger company....Our ability to attract these accomplished directors is a testament to what we have achieved so far and the opportunities ahead for Mallinckrodt."
Paul Bisaro comes with an extensive background in the healthcare industry, having led both generic and branded pharmaceutical companies. His leadership experience includes tenures as President, CEO, and director at Impax Laboratories, as well as executive roles at Amneal Pharmaceuticals (NASDAQ:AMRX), Allergan (NYSE:AGN), Actavis , and Barr Pharmaceuticals. He also has board experience with companies such as Zoetis (NYSE:ZTS) and Myriad Genetics (NASDAQ:MYGN).
Katina Dorton's financial acumen in the healthcare sector spans over two decades, with roles as CFO at various biotechnology firms and a history in healthcare investment banking at Morgan Stanley and Needham. She currently serves on the boards of Fulcrum Therapeutics (NASDAQ:FULC) and TScan Therapeutics.
Abbas Hussain brings over 30 years of leadership in healthcare, having served as CEO of Vifor Pharma and Global President of Pharmaceuticals & Vaccines at GlaxoSmithKline (NYSE:GSK). His board experiences include positions at Teva Pharmaceuticals, Aspen Pharmacare (OTC:APNHY), and Cochlear.
Wesley Wheeler's 40-year career encompasses a range of healthcare expertise, including leadership at UPS Healthcare and Patheon, as well as roles at GlaxoSmithKline and ExxonMobil (NYSE:XOM).
With these appointments, Mallinckrodt's board now consists of seven directors, including David Stetson and Jon Zinman, who joined in November 2023.
The information in this article is based on a press release statement from Mallinckrodt plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.